리가켐바이오
1 known investors
LigaChemBio is a biotechnology company focused on drug development, particularly in ADC (antibody-drug conjugate) and small molecule therapeutics. The company develops and partners on therapeutic pipelines for pharmaceutical applications.
Investors · 1
Competitors · 3
by search overlapLigachembio5 shared keywordsLigaChemBio is a biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) and small molecule therapeutics, with proprietary ADC technology and a drug development pipeline. The page shown is an investor disclosure section listing regulatory filings.
CStone Pharmaceuticals3 shared keywordsHong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with 리가켐바이오 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does 리가켐바이오 do?
- LigaChemBio is a biotechnology company focused on drug development, particularly in ADC (antibody-drug conjugate) and small molecule therapeutics. The company develops and partners on therapeutic pipelines for pharmaceutical applications.
- Who are 리가켐바이오's investors?
- 리가켐바이오's investors include Solidus Investment.